Life sciences veterans Mario Philips and Roel Gordijn have launched Enovo Life Sciences, partnering with Warburg Pincus, a prominent global growth investor. Enovo aims to identify and acquire companies to create a leading platform in the biologics and advanced therapies markets. This initiative is supported by Warburg Pincus's $17.3 billion flagship fund, WP GG 14.

Philips and Gordijn bring over 50 years of combined experience in the life sciences sector, particularly in vaccine and antibody manufacturing, as well as Advanced Therapy Medicinal Products. They previously contributed to Warburg Pincus's investment in Polyplus, a key player in cell and gene therapy solutions, which was sold for €2.4 billion to Sartorius Stedim Biotech last year.

Philips, the CEO of Enovo, emphasized the company's focus on acquiring firms with strong growth potential to build a scalable life sciences business. He noted that Enovo will provide the necessary capital for innovation, supported by Warburg Pincus's extensive global network. Gordijn expressed excitement about the opportunity to partner with leading companies across the U.S. and Europe, aiming to leverage differentiated offerings and expertise.

T.J. Carella, Managing Director at Warburg Pincus, highlighted the firm's commitment to innovative life sciences products and services, believing in the significant impact of biologics and advanced therapies on patient care. Ruoxi Chen, another Managing Director at Warburg Pincus, praised Philips and Gordijn's track record in growing global life sciences businesses, deeming them ideal leaders for this new platform.

Enovo will benefit from Warburg Pincus's resources in London, New York, and other global offices. This launch follows the appointment of Jake Strauss to lead the healthcare investing practice in Europe, reinforcing Warburg Pincus's dedication to healthcare investments.

Warburg Pincus has invested over $18 billion in more than 180 healthcare companies since its inception, with a strong focus on life sciences. The firm manages over $83 billion in assets and has a diverse portfolio of over 225 companies across various sectors and geographies.

For more information, visit Warburg Pincus's website or contact Enovo Life Sciences directly.